ReviewInternational journal of molecular sciences2019
Glucagon, GLP-1 and Thermogenesis.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05419726 (Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- A systematic review on the role of infrared thermography in the Brown adipose tissue assessment.Reviews in endocrine & metabolic disorders · 2020Pooled it
- Adipose Tissue Plasticity and Adipogenesis: From Cellular Mechanisms to Therapeutic Targets in Obesity.Current obesity reports · 2026Review
- Inhibition of daily torpor in mice requires calories, not just feeding: a potential role for GLP-1.Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology · 2026Article
- Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases.Journal of nanobiotechnology · 2025Review
- Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.Alimentary pharmacology & therapeutics · 2025Review
- White adipocyte-derived exosomal miR-23b inhibits thermogenesis by targeting Elf4 to regulate GLP-1R transcription.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Adipose Tissue Dysfunction Related to Climate Change and Air Pollution: Understanding the Metabolic Consequences.International journal of molecular sciences · 2024Review
- A combination ofFood & nutrition research · 2024Article
- The Effects of Intermittent Cold Exposure on Adipose Tissue.International journal of molecular sciences · 2023Review
- Anti-Obesity Drug Delivery Systems: Recent Progress and Challenges.Pharmaceutics · 2023Review
- Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov.Journal of multidisciplinary healthcare · 2023Review
- Brain-to-BAT - and Back?: Crosstalk between the Central Nervous System and Thermogenic Adipose Tissue in Development and Therapy of Obesity.Brain sciences · 2022Review
- Signaling pathways in obesity: mechanisms and therapeutic interventions.Signal transduction and targeted therapy · 2022Review
- The dynamic genetic architecture of early childhood BMI.Nature metabolism · 2022Article
- Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls.PloS one · 2022Article
- Transdermal Drug Delivery Systems and Their Use in Obesity Treatment.International journal of molecular sciences · 2021Review
- Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications.Cardiovascular diabetology · 2021Review
- Thermogenic Fat: Development, Physiological Function, and Therapeutic Potential.International journal of molecular sciences · 2021Review
- Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women.Nutrients · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Brown adipose tissue (BAT) thermogenesis is a conserved mechanism to maintain body temperature in mammals. However, since BAT contribution to energy expenditure can represent a relevant modulator of metabolic homeostasis, many studies have focused on the nervous system and endocrine factors that control the activity of this tissue. There is long-established evidence that the counter-regulatory hormone glucagon negatively influences energy balance, enhances satiety, and increases energy expenditure. Despite compelling evidence showing that glucagon has direct action on BAT thermogenesis, recent findings are questioning this conventional attribute of glucagon action. Glucagon like peptide-1 (GLP-1) is an incretin secreted by the intestinal tract which strongly decreases feeding, and, furthermore, improves metabolic parameters associated with obesity and diabetes. Therefore, GLP-1 receptors (GLP-1-R) have emerged as a promising target in the treatment of metabolic disorders. In this short review, we will summarize the latest evidence in this regard, as well as the current therapeutic glucagon- and GLP-1-based approaches to treating obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.